CF(cor)-325

CFTR corrector

Phase of research

Pre-clinical

How it helps

Restore CFTR Function

General information

CF(cor)-325 is an experimental substance used in studies and not yet available as a human pharmaceutical. In relation to cystic fibrosis, our AIM tool found the data that CF(cor)-325 can rescue misprocessed CFTR mutants, including F508del, R258G, S945L, and H949Y. 

CF(cor)-325 on PubChem

Synonyms

VRT-325, 4-cyclohexyloxy-2-{1-[4-(4-methoxy-benzenesulfonyl)piperazin-1-yl]ethyl}quinazoline

Marketed as

N/A

Dietary sources

N/A

Structure not available

C27H34N4O4S

Drug-Mutation Relation

Treats

Mutation Number of sources Average impact factor
F508del
1 0.00
Link Tested on Impact factor Notes
Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. human cell cultures N/A
H949Y
1 0.00
Link Tested on Impact factor Notes
Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. human cell cultures N/A
R258G
1 0.00
Link Tested on Impact factor Notes
Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. human cell cultures N/A
S945L
1 0.00
Link Tested on Impact factor Notes
Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. human cell cultures N/A

Does not treat

Mutation Number of sources Average impact factor